{"organizations": [], "uuid": "63aa9db8b5c12e862376c30d84e1c97e3e5f884f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-roche-says-late-stage-study-shows/brief-roche-says-late-stage-study-shows-genentechs-tecentriq-and-avastin-reduced-the-risk-of-disease-worsening-or-death-by-26-pct-in-certain-people-with-advanced-kidney-cancer-idUSFWN1PV1EG", "country": "US", "domain_rank": 408, "title": "BRIEF-Roche Says Late-stage Study Shows Genentech's Tecentriq And Avastin Reduced The Risk Of Disease Worsening Or Death By 26 Pct In Certain People With Advanced Kidney Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-06T00:17:00.000+02:00", "replies_count": 0, "uuid": "63aa9db8b5c12e862376c30d84e1c97e3e5f884f"}, "author": "", "url": "https://www.reuters.com/article/brief-roche-says-late-stage-study-shows/brief-roche-says-late-stage-study-shows-genentechs-tecentriq-and-avastin-reduced-the-risk-of-disease-worsening-or-death-by-26-pct-in-certain-people-with-advanced-kidney-cancer-idUSFWN1PV1EG", "ord_in_thread": 0, "title": "BRIEF-Roche Says Late-stage Study Shows Genentech's Tecentriq And Avastin Reduced The Risk Of Disease Worsening Or Death By 26 Pct In Certain People With Advanced Kidney Cancer", "locations": [], "entities": {"persons": [{"name": "avasti", "sentiment": "neutral"}], "locations": [], "organizations": [{"name": "genentech", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 5 (Reuters) - Roche Holding Ag:\n* PHASE III IMMOTION151 STUDY SHOWED GENENTECH’S TECENTRIQ (ATEZOLIZUMAB) AND AVASTIN (BEVACIZUMAB) REDUCED THE RISK OF DISEASE WORSENING OR DEATH BY 26 PERCENT IN CERTAIN PEOPLE WITH ADVANCED KIDNEY CANCER\n* GENENTECH SAYS TECENTRIQ AND AVASTIN MET CO-PRIMARY ENDPOINT\n* GENENTECH - INITIAL OBSERVATIONS FROM CO-PRIMARY ENDPOINT OF OVERALL SURVIVAL IN OVERALL STUDY POPULATION WERE “ENCOURAGING, BUT ARE STILL IMMATURE”\n* GENENTECH - RATE OF TREATMENT-RELATED GRADE 3-4 ADVERSE EVENTS LOWER WITH TECENTRIQ & AVASTIN COMBINATION VERSUS SUNITINIB IN ALL TREATED PATIENTS Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-06T00:17:00.000+02:00", "crawled": "2018-02-06T00:32:26.011+02:00", "highlightTitle": ""}